S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:JAGX

Jaguar Health (JAGX) Stock Forecast, Price & News

$0.40
+0.01 (+2.57%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.39
$0.44
50-Day Range
$0.37
$0.71
52-Week Range
$0.34
$6.84
Volume
1.77 million shs
Average Volume
929,919 shs
Market Capitalization
$30.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.82
30 days | 90 days | 365 days | Advanced Chart
Receive JAGX News and Ratings via Email

Sign-up to receive the latest news and ratings for Jaguar Health and its competitors with MarketBeat's FREE daily newsletter.

Jaguar Health logo

About Jaguar Health

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

Headlines

Jaguar Health Q1 2022 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:JAGX
Fax
N/A
Employees
52
Year Founded
N/A

Sales & Book Value

Annual Sales
$4.34 million
Book Value
$0.11 per share

Profitability

Net Income
$-52.60 million
Net Margins
-1,023.99%
Pretax Margin
-1,027.19%

Debt

Price-To-Earnings

Miscellaneous

Free Float
75,314,000
Market Cap
$30.73 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/10/2022
Today
5/22/2022
Next Earnings (Estimated)
8/12/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.83 out of 5 stars

Medical Sector

769th out of 1,416 stocks

Pharmaceutical Preparations Industry

371st out of 677 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -













Jaguar Health (NASDAQ:JAGX) Frequently Asked Questions

Is Jaguar Health a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jaguar Health in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Jaguar Health stock.
View analyst ratings for Jaguar Health
or view top-rated stocks.

Are investors shorting Jaguar Health?

Jaguar Health saw a drop in short interest in April. As of April 30th, there was short interest totaling 3,450,000 shares, a drop of 22.5% from the April 15th total of 4,450,000 shares. Based on an average daily trading volume, of 4,250,000 shares, the short-interest ratio is currently 0.8 days. Approximately 4.9% of the shares of the stock are short sold.
View Jaguar Health's Short Interest
.

When is Jaguar Health's next earnings date?

Jaguar Health is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for Jaguar Health
.

How were Jaguar Health's earnings last quarter?

Jaguar Health, Inc. (NASDAQ:JAGX) issued its quarterly earnings data on Tuesday, May, 10th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.19. Jaguar Health had a negative trailing twelve-month return on equity of 319.63% and a negative net margin of 1,023.99%. During the same quarter in the previous year, the business posted ($0.30) earnings per share.
View Jaguar Health's earnings history
.

When did Jaguar Health's stock split? How did Jaguar Health's stock split work?

Jaguar Health shares reverse split before market open on Wednesday, September 8th 2021. The 1-3 reverse split was announced on Wednesday, September 8th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 8th 2021. An investor that had 100 shares of Jaguar Health stock prior to the reverse split would have 33 shares after the split.

What price target have analysts set for JAGX?

1 Wall Street analysts have issued 1 year price objectives for Jaguar Health's stock. Their forecasts range from $5.00 to $5.00. On average, they expect Jaguar Health's stock price to reach $5.00 in the next year. This suggests a possible upside of 1,153.8% from the stock's current price.
View analysts' price targets for Jaguar Health
or view top-rated stocks among Wall Street analysts.

Who are Jaguar Health's key executives?
Jaguar Health's management team includes the following people:
  • Ms. Lisa A. Conte, Founder, CEO, Pres & Director (Age 63, Pay $525.21k)
  • Mr. Jonathan S. Wolin CPA, J.D., M.B.A., Chief of Staff, Chief Compliance Officer & Gen. Counsel (Age 60, Pay $336.51k)
  • Dr. Steven R. King, Chief Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec. (Age 64, Pay $332.23k)
  • Ms. Carol R. Lizak, Chief Financial Officer (Age 58)
  • Dr. Pravin R. Chaturvedi Ph.D., Chief Scientific Officer & Chair of Scientific Advisory Board (Age 59)
  • Mr. Peter Hodge, Sr. Director of Investor Relations, Bus. Devel. & Special Events
  • Dr. Karen J. Brunke Ph.D., Exec. VP of Corp. & Bus. Devel.
  • Mr. David Sesin, Chief Manufacturing Officer
  • Mr. Ian H. Wendt M.B.A., Chief Commercial Officer
  • Dr. Michael K. Guy D.V.M., M.S., Ph.D., VP of Preclinical & Nonclinical Studies
What other stocks do shareholders of Jaguar Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biocept (BIOC), Sorrento Therapeutics (SRNE), Trevena (TRVN), Vaxart (VXRT), Purple Biotech (KTOV), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), Biopharmx (BPMX), Cara Therapeutics (CARA) and Conatus Pharmaceuticals (CNAT).

When did Jaguar Health IPO?

(JAGX) raised $22 million in an initial public offering (IPO) on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp acted as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

What is Jaguar Health's stock symbol?

Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."

Who are Jaguar Health's major shareholders?

Jaguar Health's stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.98%), Vanguard Group Inc. (1.40%), Virtu Financial LLC (0.30%), Bank of New York Mellon Corp (0.22%), Principal Financial Group Inc. (0.15%) and Goldman Sachs Group Inc. (0.07%).
View institutional ownership trends for Jaguar Health
.

Which major investors are selling Jaguar Health stock?

JAGX stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Principal Financial Group Inc., and Group One Trading L.P..
View insider buying and selling activity for Jaguar Health
or view top insider-selling stocks.

Which major investors are buying Jaguar Health stock?

JAGX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Bank of New York Mellon Corp, Virtu Financial LLC, Citigroup Inc., and Goldman Sachs Group Inc..
View insider buying and selling activity for Jaguar Health
or or view top insider-buying stocks.

How do I buy shares of Jaguar Health?

Shares of JAGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jaguar Health's stock price today?

One share of JAGX stock can currently be purchased for approximately $0.40.

How much money does Jaguar Health make?

Jaguar Health has a market capitalization of $30.73 million and generates $4.34 million in revenue each year. The biotechnology company earns $-52.60 million in net income (profit) each year or ($1.280040) on an earnings per share basis.

How many employees does Jaguar Health have?

Jaguar Health employs 52 workers across the globe.

What is Jaguar Health's official website?

The official website for Jaguar Health is www.jaguaranimalhealth.com.

How can I contact Jaguar Health?

Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The biotechnology company can be reached via phone at (415) 371-8300.

This page was last updated on 5/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.